文献速递临床试验与 GCP基础与转化研究

放疗联合射频消融/椎体增强对比单纯放疗治疗脊柱转移瘤:随机对照试验方案

Radiation therapy alone versus radiation therapy plus radiofrequency ablation/vertebral augmentation for spine metastasis: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-11-23

本研究为单中心、前瞻性、随机对照试验,纳入T5-L5脊柱转移瘤患者,按肿瘤类型(放射抵抗vs放射敏感)分层,2:1随机接受RFA/PVA联合EBRT或单纯EBRT,EBRT剂量20-30 Gy/5-10次。主要目的是评估联合治疗是否在3个月时改善疼痛控制(NRPS完全或部分缓解),次要目标包括疼痛缓解速度、持续时间、患者报告疼痛影响、健康效用和整体生活质量。

要点

  • 脊柱转移瘤患者随机接受RFA/PVA+EBRT或单纯EBRT,分层因素为肿瘤放射敏感性。
  • 主要终点为3个月时NRPS疼痛完全或部分缓解,联合治疗可能提高疼痛缓解率。
  • EBRT方案为20-30 Gy分5-10次,联合治疗组额外接受RFA/PVA。

核心结论

  • 旨在确定RFA/PVA联合EBRT是否较单纯姑息性EBRT改善脊柱转移瘤患者的疼痛控制。

研究设计与样本

  • 单中心、前瞻性、随机对照试验,纳入T5-L5脊柱转移瘤患者,按肿瘤类型(放射抵抗vs放射敏感)分层。
  • 每层患者按2:1比例随机分配至RFA/PVA联合EBRT组或单纯EBRT组。
  • 所有患者接受EBRT剂量20-30 Gy分5-10次。

关键数值与推荐

  • 主要终点为3个月时使用NRPS测量的疼痛完全或部分缓解。
  • 次要终点包括疼痛缓解速度、疼痛缓解持续时间、患者报告疼痛影响、健康效用和整体生活质量。
  • EBRT剂量为20-30 Gy分5-10次。

临床怎么用

  • 若联合治疗有效,可为脊柱转移瘤患者提供一种改善疼痛控制和生活质量的联合策略。

局限性

  • 单中心设计可能限制结果外推性。
  • 样本量未在摘要中报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Spine metastasis is a common occurrence in cancer patients and results in pain, neurologic deficits, decline in performance status, disability, inferior quality of life (QOL), and reduction in ability to receive cancer-directed therapies. Conventional external beam radiation therapy (EBRT) is associated with modest rates of pain relief, high rates of disease recurrence, low response rates for those with radioresistant histologies, and limited improvement in neurologic deficits. The addition of radiofrequency ablation/percutaneous vertebral augmentation (RFA/PVA) to index sites together with EBRT may improve pain response rates and corresponding quality of life. METHODS/DESIGN: This is a single-center, prospective, randomized, controlled trial in patients with spine metastasis from T5-L5, stratified according to tumor type (radioresistant vs. radiosensitive) in which patients in each stratum will be randomized in a 2:1 ratio to either RFA/PVA and EBRT or EBRT alone. All patients will be treated with EBRT to a dose of 20-30 Gy in 5-10 fractions. The target parameters will be measured and recorded at the baseline clinic visit, and daily at home with collection of weekly measurements at 1, 2, and 3 weeks after treatment, and at 3, 6, 12, and 24 months following treatment with imaging and QOL assessments. DISCUSSION: The primary objective of this randomized trial is to determine whether RFA/PVA in addition to EBRT improves pain control compared to palliative EBRT alone for patients with spine metastasis, defined as complete or partial pain relief (measured using the Numerical Rating Pain Scale [NRPS]) at 3 months. Secondary objectives include determining whether combined modality treatment improves the rapidity of pain response, duration of pain response, patient reported pain impact, health utility, and overall QOL. TRIAL REGISTRATION: ClinicalTrials.gov NCT04375891 . Registered on 5 May 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Kotecha R, Schiro BJ, Sporrer J, et al. Radiation therapy alone versus radiation therapy plus radiofrequency ablation/vertebral augmentation for spine metastasis: study protocol for a randomized controlled trial. Trials. 2020. PMID: 33228756. doi:10.1186/s13063-020-04895-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。